These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32966719)

  • 1. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
    Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
    N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on.
    Mullard A
    Nat Rev Drug Discov; 2018 Dec; 17(12):850-851. PubMed ID: 30443037
    [No Abstract]   [Full Text] [Related]  

  • 4. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA committee urges tight restrictions on rosiglitazone.
    Roehr B
    BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosiglitazone and the FDA.
    Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
    N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
    [No Abstract]   [Full Text] [Related]  

  • 7. Rosiglitazone: what went wrong?
    Cohen D
    BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA puts restrictions on use of controversial diabetes drug.
    Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
    Low Wang CC; Everett BM; Burman KD; Wilson PWF
    Circulation; 2019 Apr; 139(14):1741-1743. PubMed ID: 30933621
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
    Gore MO; McGuire DK
    Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
    Freemantle N
    BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular trials and diabetes treatments: a regulatory maze.
    Matthews DR
    Diab Vasc Dis Res; 2012 Apr; 9(2):83-4. PubMed ID: 22419242
    [No Abstract]   [Full Text] [Related]  

  • 14. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Yin and the Yang of CV risks in patients with diabetes.
    Dangi-Garimella S
    Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA rejects novel diabetes drug over safety fears.
    Burki TK
    Lancet; 2012 Feb; 379(9815):507. PubMed ID: 22334883
    [No Abstract]   [Full Text] [Related]  

  • 17. Rosiglitazone and cardiovascular risk.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
    Nat Rev Drug Discov; 2009 Feb; 8(2):99. PubMed ID: 19180100
    [No Abstract]   [Full Text] [Related]  

  • 19. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
    Schmidt TA; Rosen CJ; Yudkin JS
    BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of cardiovascular outcome trials in type 2 diabetes.
    Cypryk K; Małecki P
    Endokrynol Pol; 2018; 69(4):. PubMed ID: 30209802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.